vs
Expensify, Inc.（EXFY）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Expensify, Inc.的季度营收约是REGENXBIO Inc.的1.2倍（$35.2M vs $30.3M），REGENXBIO Inc.同比增速更快（43.0% vs -4.9%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 2.4%）
Expensify Inc.是一家软件服务企业，主打面向个人与企业用户开发费用管理系统，助力用户便捷高效地完成费用报销、账单统计等工作，此外该公司还推出了名为Expensify Card的商务信用卡产品。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
EXFY vs RGNX — 直观对比
营收规模更大
EXFY
是对方的1.2倍
$30.3M
营收增速更快
RGNX
高出47.9%
-4.9%
两年增速更快
RGNX
近两年复合增速
2.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $35.2M | $30.3M |
| 净利润 | — | $-67.1M |
| 毛利率 | 49.2% | — |
| 营业利润率 | -11.2% | -190.0% |
| 净利率 | — | -221.3% |
| 营收同比 | -4.9% | 43.0% |
| 净利润同比 | — | -31.2% |
| 每股收益（稀释后） | $-0.07 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXFYRGNX
| Q4 25 | $35.2M | $30.3M | ||
| Q3 25 | $35.1M | $29.7M | ||
| Q2 25 | $35.8M | $21.4M | ||
| Q1 25 | $36.1M | $89.0M | ||
| Q4 24 | $37.0M | $21.2M | ||
| Q3 24 | $35.4M | $24.2M | ||
| Q2 24 | $33.3M | $22.3M | ||
| Q1 24 | $33.5M | $15.6M |
净利润EXFYRGNX
| Q4 25 | — | $-67.1M | ||
| Q3 25 | $-2.3M | $-61.9M | ||
| Q2 25 | $-8.8M | $-70.9M | ||
| Q1 25 | $-3.2M | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $-2.2M | $-59.6M | ||
| Q2 24 | $-2.8M | $-53.0M | ||
| Q1 24 | $-3.8M | $-63.3M |
毛利率EXFYRGNX
| Q4 25 | 49.2% | — | ||
| Q3 25 | 49.6% | — | ||
| Q2 25 | 51.9% | — | ||
| Q1 25 | 50.6% | — | ||
| Q4 24 | 51.0% | 70.2% | ||
| Q3 24 | 51.6% | 48.8% | ||
| Q2 24 | 56.9% | 52.5% | ||
| Q1 24 | 56.5% | 72.6% |
营业利润率EXFYRGNX
| Q4 25 | -11.2% | -190.0% | ||
| Q3 25 | -6.4% | -176.3% | ||
| Q2 25 | -28.9% | -296.3% | ||
| Q1 25 | -4.1% | 13.6% | ||
| Q4 24 | 1.3% | -242.1% | ||
| Q3 24 | 0.8% | -256.6% | ||
| Q2 24 | 0.7% | -251.3% | ||
| Q1 24 | -5.3% | -408.8% |
净利率EXFYRGNX
| Q4 25 | — | -221.3% | ||
| Q3 25 | -6.6% | -208.3% | ||
| Q2 25 | -24.6% | -331.8% | ||
| Q1 25 | -8.8% | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | -6.2% | -246.3% | ||
| Q2 24 | -8.3% | -237.7% | ||
| Q1 24 | -11.3% | -405.4% |
每股收益（稀释后）EXFYRGNX
| Q4 25 | $-0.07 | $-1.30 | ||
| Q3 25 | $-0.03 | $-1.20 | ||
| Q2 25 | $-0.10 | $-1.38 | ||
| Q1 25 | $-0.03 | $0.12 | ||
| Q4 24 | $-0.03 | $-0.99 | ||
| Q3 24 | $-0.02 | $-1.17 | ||
| Q2 24 | $-0.03 | $-1.05 | ||
| Q1 24 | $-0.04 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.1M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $132.7M | $102.7M |
| 总资产 | $186.0M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXFYRGNX
| Q4 25 | $63.1M | $230.1M | ||
| Q3 25 | $61.5M | $274.2M | ||
| Q2 25 | $60.5M | $323.3M | ||
| Q1 25 | $59.6M | $267.9M | ||
| Q4 24 | $48.8M | $234.7M | ||
| Q3 24 | $39.2M | $255.5M | ||
| Q2 24 | $53.2M | $290.4M | ||
| Q1 24 | $49.3M | $338.7M |
股东权益EXFYRGNX
| Q4 25 | $132.7M | $102.7M | ||
| Q3 25 | $135.7M | $161.5M | ||
| Q2 25 | $131.8M | $213.7M | ||
| Q1 25 | $134.7M | $274.2M | ||
| Q4 24 | $128.2M | $259.7M | ||
| Q3 24 | $119.9M | $301.4M | ||
| Q2 24 | $114.0M | $348.3M | ||
| Q1 24 | $106.5M | $390.7M |
总资产EXFYRGNX
| Q4 25 | $186.0M | $453.0M | ||
| Q3 25 | $186.8M | $525.2M | ||
| Q2 25 | $187.1M | $581.0M | ||
| Q1 25 | $189.2M | $490.9M | ||
| Q4 24 | $173.7M | $466.0M | ||
| Q3 24 | $176.2M | $519.1M | ||
| Q2 24 | $192.9M | $569.4M | ||
| Q1 24 | $184.8M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.2M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流EXFYRGNX
| Q4 25 | $2.2M | $-52.3M | ||
| Q3 25 | $4.2M | $-56.0M | ||
| Q2 25 | $8.9M | $-49.3M | ||
| Q1 25 | $4.8M | $33.6M | ||
| Q4 24 | $7.4M | $-31.6M | ||
| Q3 24 | $3.7M | $-40.5M | ||
| Q2 24 | $9.3M | $-45.5M | ||
| Q1 24 | $3.5M | $-55.5M |
自由现金流EXFYRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率EXFYRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度EXFYRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | 0.0% | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | 0.0% | 5.1% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | 0.0% | 2.1% | ||
| Q1 24 | 0.0% | 3.6% |
现金转化率EXFYRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXFY
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
